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Abstract 
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We built a Markov model to predict the outcomes and cost-effectiveness of bevacizumab compared to 
macular laser therapy for diabetes patients with clinically significant macular oedema (CSMO).  We 
used outcome data from an RCT, utility data and health states from a ranibizumab health technology 
assessment (HTA), and costs from the UK National Tariff. 
37.73% of patients treated with bevacizumab in the model had a visual acuity of at least 76 ETDRS 
letters after four years, compared with 4.09% of laser therapy patients.  Also, only 0.11% of 
bevacizumab patients were blind after four years, compared with 6.45% of laser therapy patients.  
However, with an ICER of £51,182, we predict that bevacizumab would not be cost-effective 
compared to laser therapy because of the influence of the NHS national tariff costs for monitoring 
patients and administering bevacizumab, and the EQ-5D’s inability to sufficiently capture the impact 
of sensory deprivation on quality of life.  We therefore advise significant caution when interpreting 
the results of cost-effectiveness analyses of interventions that involve vision-related interventions. 
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Key Points 
 We undertook a cost-effectiveness analysis of bevacizumab compared to laser therapy for 
treating Diabetic Macular Oedema 
 Our model predicts that bevacizumab would lead to significant improvements to visual acuity 
for patients 
 Our model also predicts that bevacizumab is not considered to be cost-effective because of 
but the inadequacy of conventional quality of life measures to capture the impact on quality of 
life of sensory deprivation 
 We would advise caution when interpreting results of cost-effectiveness analyses that assess 
vision-related interventions 
 We strongly encourage the research, development and uptake of quality of life measures that 
adequately capture the impact of sensory deprivation on quality of life 
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Introduction 
Diabetic Macular Oedema (DMO) has been treated for many years with macular laser therapy (MLT), 
which is largely successful at slowing the deterioration of visual acuity (Early Treatment Diabetic 
Retinopathy Study Research Group, 1985).  However, there are concerns that laser therapy is, 
effectively, a destructive intervention which can cause scarring, and can lead to further deterioration 
of visual acuity if the laser scars enlarge (Schatz et al, 1991).  Furthermore, some patients are unable 
to receive or be fully treated with laser therapy because the oedema involves the fovea, or are 
otherwise refractory to laser (Bailey et al, 1999).  This has prompted an interest in alternative 
treatments for DMO.  Anti-VEGFs such as ranibizumab and bevacizumab may offer a means to 
improve visual acuity (Mitchell et al, 2012; Rajendram et al, 2012), and treat patients who are 
refractory to laser, or for whom laser cannot be used to remove all of the oedema. 
 
The cost-effectiveness of ranibizumab for the treatment of DMO has been previously reported 
(Mitchell et al, 2012), and is now recommended by the National Institute for Health and Care 
Excellence (NICE) following an initial decision not to recommend the drug (NICE, 2013).  Whilst the 
details of the revised Patient Access Scheme are confidential, generally bevacizumab is a much 
cheaper drug than ranibizumab (Raftery et al, 2007), and therefore may represent a more cost-
effective alternative treatment.  The BOLT (Bevacizumab or Laser Therapy) study (Michaelides et al, 
2010; Rajendram et al, 2012) was a two-year randomised controlled trial that compared the visual 
acuity outcomes of two groups of patients with centre-involved clinically significant macular oedema 
(CSMO), one of which was treated with bevacizumab and one with macular laser therapy.  The study 
reports a mean gain of 8.6 ETDRS (Early Treatment Diabetic Retinopathy Study) letters for the 
bevacizumab group, compared to a mean loss of 0.5 ETDRS letters for the laser therapy group. 
 
In this study, we report the findings from a cost-effectiveness analysis of bevacizumab for the 
treatment of DMO, compared with macular laser therapy.  We use the reported two-year outcomes 
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from the BOLT study, along with costs from the UK NHS cost schedule (Department of Health, 2012) 
and utilities and health states from the ranibizumab for DMO cost-effectiveness analysis (Mitchell et 
al, 2012).  We predict the visual acuity outcomes and cost-effectiveness over a four year period for 
both treatments, which represents a trade-off between minimising the period of time for which we do 
not have effectiveness data, and allowing sufficient time for cost and quality of life benefits to 
emerge.  Furthermore, we demonstrate that bevacizumab is not considered to be cost-effective in such 
an analysis, in part due to the inability to adequately capture the impact on vision-impacted quality of 
life in such analyses. 
 
Methods 
Introduction to Methods 
We developed a Markov model to assess the incremental expected costs and quality of life of 
bevacizumab for the treatment of DMO, compared with macular laser therapy.  In a Markov model, 
patients move through various health states, which correspond to the progression of a disease, or 
complications that can arise.  In our model, two cohorts of 100,000 CSMO patients progress over a 
four-year time horizon, with time progressing in 28-day cycles.  One cohort is assigned to receive 
bevacizumab treatment, whilst the other receives macular laser therapy. 
 
Each health state is assigned an associated utility, which attempts to quantify a patient's quality of life 
when they are in this health state.  In addition, a health state may have associated costs for treatment, 
support and monitoring.  Our model adopted the perspective of the NHS and Personal Social Services, 
and therefore only these costs were included. 
 
Health States 
Since we are determining patient outcomes in terms of visual acuity, the health states in our model 
represent various levels of visual acuity, specified in terms of an assessment of ETDRS best-corrected 
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visual acuity (BCVA).  Specifically, we use the health states implemented by the ranibizumab for 
DMO cost-effectiveness analysis (Mitchell et al, 2012), in which each health state represents a 10-
letter range of visual acuity, except for the lowest (≤ 25 letters) and highest (86-100 letters).  The 
health state representing a visual acuity of ≤ 25 letters corresponds to patients who are blind (WHO, 
2010), and patients in this health state cannot improve in the model, as they receive no further 
treatment.  We also have an additional health state to represent patients who have died ("Death").  
Figure 1 shows the health states used in our model, and the possible transitions between them for each 
28 day cycle.  At the start of the model, all patients have visual acuities between 36 and 75 ETDRS 
letters - approximating the baseline characteristics of the BOLT study (Michaelides et al, 2010) - and 
are distributed uniformly across the four health states in this range. 
 
Figure 1.  Health states in the model and the potential transitions between them. 
 
Utilities 
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Utility values weight the time spent in health states according to the expected quality of life associated 
with being in that health state.  We explored a number of alternatives to determine the utility levels 
appropriate for each health state in our model (Brown et al, 1999; Misajon et al, 2005; Lloyd et al, 
2008).  Vision-specific quality of life measures potentially offer a means of better capturing aspects of 
sensory deprivation than traditional MAU models such as the EQ-5D (Misajon et al, 2005; Lloyd et al, 
2008), but measures such as the VisQoL (Misajon et al, 2005) are sparsely referenced in the literature, 
and seem to have a poor uptake.  We therefore used the utility scores provided by Mitchell et al 
(Mitchell et al, 2012) to populate the utility scores in our model (Table 1), which were derived from 
EQ-5D scores in the RESTORE trial, and then converted to represent a UK population.  Using EQ-5D 
scores is the preferred approach of NICE (NICE, 2008), and the study demonstrated that the scores 
derived were similar to those found in the Brown et al (1999) and Lloyd et al (2008) studies. 
 
Treatment and Monitoring Regimens 
The treatment and monitoring regimens used in the model are based on the BOLT study (Rajendram 
et al, 2012), with some amendments made in consultation with local clinicians to better approximate 
clinical practice in the UK.  Patients treated with bevacizumab receive a 1.25mg dose of the drug in 
each injection, and are monitored and assessed for treatment every six weeks.  BOLT reports that the 
median number of injections received per patient in the first year was nine, and in the second year was 
four.  Therefore, patients in our model receive an injection at baseline and every six weeks thereafter 
in the first year, and every 12 weeks in the second year. 
 
Patients treated with macular laser therapy are monitored and assessed for treatment every three 
months.  BOLT reports that patients attended a median of three laser therapy sessions in the first year, 
and just one in the second year.  Therefore, in our model, patients receive laser therapy at baseline, at 
six months and at 12 months in year one, and six months into year two.  For both the bevacizumab 
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and laser therapy regimens, we assume that the treatment frequency for years three and four is the 
same as year two. 
 
Outcomes 
The BOLT study reports the two-year visual acuity outcomes in terms of visual acuity changes from 
baseline.  We find that, within two years, for those treated with bevacizumab : (i) 32% gained at least 
15 ETDRS letters, (ii) 17% gained between 10 and 14 ETDRS letters, and (iii) 51% gained less than 
10 ETDRS letters or lost less than 15 ETDRS letters. 
 
We assume that 95% of the 'stabilisation' group (the 51% that gained less than 10 letters or lost less 
than 15 letters) gained or lost less than 10 letters, which would result in no change in health state in 
our model.  This implies that 2.6% of patients lost between 10 and 14 letters (inclusive), which is 
similar to the visual acuity deterioration rate of 3.5% observed with ranibizumab treatment (European 
Medicines Agency, 2011). 
 
For laser therapy, we find that, within two years, (i) 4% gained at least 15 ETDRS letters, (ii) 3% 
gained between 10 and 14 ETDRS letters, (iii) 79% gained less than 10 ETDRS letters or lost less 
than 15 ETDRS letters, and (iv) 14% lost 15 ETDRS letters or more.  Again, we assume that 95% of 
the 'stabilisation' group gained or lost less than 10 letters, which implies that 3.95% of patients lost 
between 10 and 14 letters (inclusive), similar to the 5% deterioration rate reported by a Diabetic 
Retinopathy Clinical Research Network (DRCRN) study (Elman et al, 2010). 
 
For simplicity, we assume that a gain or loss of at least 15 letters translates to a gain or loss of two 
health states in the model. 
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Mortality 
The mortality rate for patients in the model was taken from the ranibizumab HTA by Mitchell et al 
(Mitchell et al, 2012).  Specifically, patients in the model are 2.45 times more likely to die than their 
same-age, same-gender equivalents in the general population.  This risk ratio incorporates the 
increased risk of death from type 2 diabetes, and the increased risk of death from CSMO.  
Background mortality rates were taken from UK Interim Life Tables (Office for National Statistics, 
2009).  The cohort of patients used to initially populate the model are aged 64, and 69% of them are 
male (Michaelides et al, 2010). 
 
Adverse Events 
Bevacizumab is associated with a range of minor injection-related adverse events, such as red-eye and 
irritation (Michaelides et al, 2010; Rajendram et al, 2012), but these do not typically prevent further 
treatment for the patient or affect the patient's long-term quality of life, and are therefore excluded 
from our model.  Patients treated with bevacizumab have a small risk of developing retinal 
detachment, estimated to affect around 0.19% of bevacizumab patients within one year (Wu et al, 
2008).  It is expected that around 85% of patients who develop retinal detachment would be 
successfully treated with a vitrectomy (James et al, 2002).  Whilst the remaining 15% would normally 
undergo a second procedure (James et al, 2002), for simplification we here assume that these patients 
for whom the first procedure was unsuccessful lose their vision (Flynn et al, 1992) (visual acuity of 25 
ETDRS letters or fewer).  We also assume that patients who suffer from vitreous haemorrhage lose 
their vision (Flynn et al, 1992), as the risk of this adverse event for patients treated with bevacizumab 
is very small, at around 0.02% within one year (Wu et al, 2008). 
 
Patients treated with macular laser therapy may suffer from laser burn causing scarring, and the 
enlargement of laser scars can affect visual acuity (Schatz et al, 1991).  The BOLT study reports that 
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14% of patients treated with macular laser therapy lost 15 ETDRS letters or more within two years 
(Rajendram et al, 2012), and we implement this as a probability of deteriorating by two health states 
in our model.  It is likely that at least a proportion of these patients in the BOLT study significantly 
lost their vision because of laser scar enlargement, as studies have found that around 5% of laser-
treated patients are affected by this (Schatz et al, 1991; Rutledge et al, 1993). 
 
Costs 
We derived costs from the UK National Tariff of healthcare costs for 2011-2012 (Department of 
Health, 2012), and based our estimates of resource usage on the opinion of local clinicians.  Table 2 
provides details of the costs used in the model.  A 3.5% annual discount rate is applied to costs and 
benefits in the model. 
 
Results 
In our model, 37.73% of the 100,000 patients treated with bevacizumab had a visual acuity of at least 
75 ETDRS letters after four years, compared with just 4.09% of patients treated with macular laser 
therapy.  In addition, only 0.11% of bevacizumab patients were 'blind' (visual acuity of 25 ETDRS 
letters or fewer) after four years, compared to 6.45% of laser therapy patients.  The distribution of 
visual acuity outcomes after four years for both treatments is shown in figure 2. 
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Figure 2.  Distribution of patients across the nine health states in the model after four years have 
elapsed, comparing bevacizumab-treated patients with macular laser therapy-treated patients. 
 
There is a large difference in costs between the two treatments, as we predict that bevacizumab would 
cost the NHS £5,503.88 more per patient over four years.  We predict the difference in utilities to be 
relatively minor, with a gain of just 0.1075 QALYs per patient for bevacizumab compared to laser 
therapy.  The incremental cost-effectiveness ratio (ICER) for bevacizumab compared with macular 
laser therapy is £51,182 per QALY.  Therefore, bevacizumab is unlikely to be considered cost-
effective compared to laser therapy using the standard NICE willingness-to-pay range of £20,000 to 
£30,000 per QALY (NICE, 2008).  Table 3 provides a detailed breakdown of the marginal costs and 
utilities between the bevacizumab and laser therapy treatments. 
 
Discussion 
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Whilst we predict that bevacizumab would lead to significantly improved clinical outcomes within 
four years for patients with Diabetic Macular Oedema, which could lead to important quality of life 
changes such as the ability to drive, we found that our cost-effectiveness results did not reflect this.  
Atypically for a cost-effectiveness analysis, the majority of the cost associated with bevacizumab 
treatment is for the intravitreal administration of the drug and monitoring, rather than the drug itself. 
 
We also found only a small gain in Quality Adjusted Life Years (QALYs) when using bevacizumab 
compared to laser therapy, despite the model’s prediction that significantly fewer patients would lose 
their vision when treated with bevacizumab, and significantly more patients would regain the best 
levels of visual acuity.  It has been argued that measures such as the EQ-5D do not sufficiently 
capture aspects of sensory deprivation (Misajon et al, 2005; Lloyd et al, 2008), and therefore may not 
adequately quantify the quality of life of diabetic macular oedema patients living with visual 
impairment.  Additionally, local clinicians advised us that they would have expected to see a much 
more pronounced deterioration in utility values after a patient drops below 76 letters of visual acuity, 
because it is at this stage that patients lose the ability to drive and to carry out other everyday tasks.  
We would therefore strongly encourage the development and utilisation of measures that can better 
represent the impact of eye disease on a patient’s quality of life. 
 
In conclusion, our model predicts that bevacizumab is not a cost-effective treatment for diabetic 
macular oedema, compared to conventional macular laser therapy.  The tariff costs of treatment and 
monitoring, coupled with the frequency of bevacizumab injections needed, and the regularity with 
which patients need to be monitored to promptly identify visual acuity deterioration, preclude a cost-
effective treatment option.  However, the significant visual acuity benefits of bevacizumab treatment 
seem to be underrepresented in the cost-effectiveness analysis, because of the inability of quality of 
life measures such as the EQ-5D to capture the impact of visual deterioration, which is the primary 
outcome of diabetic macular oedema.  This has been a long recognised issue, and we believe it is time 
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that further research attempts to better quantify aspects of visual impairment in quality of life 
measures, in order to ensure that future cost-effectiveness analyses that assess interventions that affect 
visual acuity are more reliable and informative.  In the meantime, we would advise caution when 
interpreting the results of any cost-effectiveness analysis that assesses vision-related interventions. 
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Tables 
Table 1.  Utility scores associated with each health state in the model.  Utility scores derived from 
Mitchell et al (2012). 
Health State Utility Value 
86-100 Letters 0.86 
76-85 Letters 0.86 
66-75 Letters 0.813 
56-65 Letters 0.802 
46-55 Letters 0.77 
36-45 Letters 0.76 
26-35 Letters 0.681 
≤ 25 Letters 0.547 
Death 0 
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Table 2.  Details of the costs used in the model. 
Description of Cost Cost Source(s) 
Single 1.25mg dose of bevacizumab (pre-
packaged 0.2ml syringe) 
£48 + £2 delivery 
charge 
Liverpool and Broadgreen NHS 
Manufacturing Unit 
Bottle of post-injection eye drops 
(Chloramphenicol 0.5%) 
£1.67 Department of Health, 2012 
Intravitreal administration of bevacizumab £145 UK National Tariff (Department of 
Health, 2012) (HRG BZ23Z Vitreous 
Retinal Procedures Category 1) 
Single session of laser therapy £145 UK National Tariff (Department of 
Health, 2012) (HRG BZ23Z Vitreous 
Retinal Procedures Category 1) 
Initial outpatient monitoring visit (for either 
treatment) 
£285 £112 consultant-led examination 
(Department of Health, 2012) 
£173 fluorescein angiography and 
tomography evaluation of the retina 
(HRG BZ23Z Vitreous Retinal 
Procedures Category 2) 
Subsequent outpatient monitoring visit (for 
either treatment) 
£210 £65 follow-up consultant-led 
examination (Department of Health, 
2012) 
£145 Tomography evaluation of the 
retina (Department of Health, 2012) 
(HRG BZ23Z Vitreous Retinal 
Procedures Category 1) 
Treating bevacizumab patient who has 
developed retinal detachment 
£1,384 £1,124 vitrectomy using the pars plana 
approach (Department of Health, 2012) 
(BZ23Z Vitreous Retinal Procedures 
Category 2 (day case)) 
Four £65 follow-up ophthalmology visits 
(Department of Health, 2012) 
Treating bevacizumab patient who has 
suffered vitreous haemorrhage 
£1,254 £1,124 vitrectomy using the pars plana 
approach (Department of Health, 2012) 
(BZ23Z Vitreous Retinal Procedures 
Category 2 (day case)) 
Two £65 follow-up ophthalmology visits 
(Department of Health, 2012) 
Cost of blindness (Patients with visual acuity 
of 25 ETDRS letters or fewer (WHO, 2010)) 
£6,477.22 per year 
per patient 
Mitchell et al, 2012 
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Table 3.  Details of the marginal costs and utilities between the bevacizumab and macular laser 
therapy treatments. 
Health State 
Discounted QALYs 
(Bevacizumab 
Pathway) 
Discounted QALYs   
(Laser Therapy Pathway) Difference in QALYs 
86-100 Letters 31,286.33 3,105.36 28,180.97 
76-85 Letters 35,412.52 4,628.91 30,783.61 
66-75 Letters 67,176.09 61,806.83 5,369.26 
56-65 Letters 64,172.61 63,184.87 987.74 
46-55 Letters 48,488.13 65,406.62 -16,918.49 
36-45 Letters 41,739.71 63,332.41 -21,592.70 
26-35 Letters 746.14 10,026.83 -9,280.69 
≤ 25 Letters 109.42 6,958.82 -6,849.40 
Retinal Detachment 73.29 0 73.29 
Death 0 0 0 
Total 289,204.24 278,450.65 10753.59 
Total (Per Person) 2.8920 2.7845 0.1075 
Cost Description 
Cost   
(Bevacizumab 
Pathway) 
Cost                           
(Laser Therapy Pathway) Difference in Costs 
Drug and administration cost £372,552,473 £77,132,276 £295,420,197 
Monitoring costs £656,487,008 £322,043,233 £334,443,775 
Cost of Adverse Event : Retinal 
Detachment £646,251 £0 £646,251 
Cost of Adverse Event : 
Vitreous Hemorrhage £117,110 £0 £117,110 
Cost of Adverse Event : 
Cataract Surgery Required £0 £0 £0 
Cost of Adverse Event : 
Glaucoma Medication Required £0 £0 £0 
Cost of Adverse Event : Sterile 
Endophthalmitis £0 £0 £0 
Cost of Blindness £2,163,468 £82,402,274 -£80,238,806 
Total £1,031,966,310 £481,577,784 £550,388,526 
Total (Per Person) £10,319.66 £4,815.78 £5,503.88 
Cost/QALY   £51,182 
 
